Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Free Cash Flow (2016 - 2025)

Viking Therapeutics' Free Cash Flow history spans 12 years, with the latest figure at -$85.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 173.53% year-over-year to -$85.3 million; the TTM value through Dec 2025 reached -$278.7 million, down 217.45%, while the annual FY2025 figure was -$278.7 million, 217.45% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$85.3 million at Viking Therapeutics, up from -$94.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$6.1 million in Q1 2024 and bottomed at -$94.0 million in Q3 2025.
  • The 5-year median for Free Cash Flow is -$15.6 million (2022), against an average of -$26.8 million.
  • The largest annual shift saw Free Cash Flow skyrocketed 75.11% in 2024 before it tumbled 753.13% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$12.4 million in 2021, then rose by 11.53% to -$10.9 million in 2022, then tumbled by 61.45% to -$17.6 million in 2023, then crashed by 76.76% to -$31.2 million in 2024, then crashed by 173.53% to -$85.3 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Free Cash Flow are -$85.3 million (Q4 2025), -$94.0 million (Q3 2025), and -$47.1 million (Q2 2025).